As novel treatment options like KRAS inhibition or immunotherapies undergo evaluation for efficacy against pancreatic cancer, it will be intriguing to see whether differential responses based on molecular features distinctly associated with race may emerge toward therapeutics targeting specific biological domains. The gene discussed is KRAS; the disease is pancreatic neoplasm.